Clinical Trial

Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

Study acronym: TRIUMPH
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2023 (before its estimated December 2023 completion). Its status may not reflect the trial's current state.
Summary
The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-06-08; most recent amendment 2024-09-13.
Status change: Active, Not Recruiting → Completed 2024-09-13
Status change: Recruiting → Active, Not Recruiting 2023-10-23
Trial Details
NCT Number NCT04925973
Lead Sponsor McMaster University
Collaborators: University of Manitoba, University of British Columbia, McGill University, University of Alberta
Conditions Ulcerative Colitis Acute
Enrollment 24 participants
Start Date 2021-06-01
Primary Completion 2023-12 (estimated)
Study Completion 2023-12 (estimated)
Updated on ClinicalTrials.gov 2023-10-24